CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis

被引：1

作者：

Soo, R. A. ^{[1
]}

Cho, B. C. ^{[2
]}

Kim, J-H. ^{[3
]}

Ahn, M-J. ^{[4
]}

Lee, K. H. ^{[5
,12
]}

Zimina, A. ^{[6
]}

Orlov, S. ^{[7
]}

Bondarenko, I. ^{[8
]}

Lee, Y-G. ^{[9
]}

Ni, L. Yueh ^{[10
]}

Lee, S. S. ^{[11
]}

Lee, K. H. ^{[5
,12
]}

Pang, Y. K. ^{[13
]}

Fong, C. H. ^{[14
]}

Kang, J. H. ^{[15
]}

Lim, C. S. ^{[16
]}

Danchaivijitr, P. ^{[17
]}

Lee, H. ^{[18
]}

Park, S. ^{[18
]}

Cicin, I. ^{[19
]}

机构：

[1] Natl Univ Canc Inst Singapore, Haematol Oncol Dept, Singapore, Singapore

[2] Yonsei Univ, Yonsei Canc Ctr, Internal Med, Coll Med, Seoul, South Korea

[3] CHA Bundang Med Ctr, Seongnam, South Korea

[4] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr, Sch Med, Seoul, South Korea

[5] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Dept Med, Coll Med, Cheongju, South Korea

[6] State Budgetary Healthcare Inst Omsk Reg, Omsk, Russia

[7] Pavlov State Med Univ, Oncol, St Petersburg, Russia

[8] Dnipropetrovsk Med Acad, Oncol & Med Radiol Dept, Dnipro, Ukraine

[9] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Sch Med, Seoul, South Korea

[10] Hosp Umum Sarawak, Sarawak, Malaysia

[11] Inje Univ, Haeundae Paik Hosp, Coll Med, Busan, South Korea

[12] Yeungnam Univ, Dept Internal Med, Med Ctr, Daegu, South Korea

[13] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia

[14] Hosp Pulau Pinang, Dept Radiotherapy & Oncol, Georgetown, Malaysia

[15] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med, Seoul, South Korea

[16] Hosp Sultan Ismail, Oncol Dept, Johor Baharu, Malaysia

[17] Mahidol Univ, Fac Med, Dept Med, Siriraj Hosp, Bangkok, Thailand

[18] Yuhan Corp, Seoul, South Korea

[19] Trakya Univ, Med Oncol Dept, Med Fac, Edirne, Turkiye

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2357

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1324MO

引用

页数：2

共 50 条

[1] Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis
Soo, Ross A.
Cho, Byoung Chul
Kim, Joo-Hang
Ahn, Myung-Ju
Lee, Ki Hyeong
Zimina, Anastasia
Orlov, Sergey
Bondarenko, Igor
Lee, Yun-Gyoo
Lim, Yueh Ni
Lee, Sung Sook
Lee, Kyung-Hee
Pang, Yong Kek
Fong, Chin Heng
Kang, Jin Hyoung
Lim, Chun Sen
Danchaivijitr, Pongwut
Kilickap, Saadettin
Yang, James Chih-Hsin
Arslan, Cagatay
Lee, Hana
Park, Seong Nam
Cicin, Irfan
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (12) : 1756 - 1766
[2] Lazertinib vs Gefitinib in Treatment-Naive Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis
Reungwetwattana, T.
Cho, B. C.
Lee, K. H.
Pang, Y. K.
Fong, C. H.
Kang, J. H.
Lee, Y. -G.
Lim, C. S.
Danchaivijitr, P.
Lim, Y. N.
Lee, Y.
How, S. H.
Geater, S.
Lee, S. S.
Min, Y. J.
Kim, J. -H.
Lee, J. -S.
Lee, G. -W.
Soo, R. A.
Choi, S.
Lee, S. Y.
Ahn, M. -J.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S331 - S331
[3] Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
Lee, Ki Hyeong
Cho, Byoung Chul
Ahn, Myung-Ju
Lee, Yun-Gyoo
Lee, Youngjoo
Lee, Jong-Seok
Kim, Joo-Hang
Min, Young Joo
Lee, Gyeong-Won
Lee, Sung Sook
Lee, Kyung-Hee
Ko, Yoon Ho
Shim, Byoung Yong
Kim, Sang-We
Shin, Sang Won
Choi, Jin-Hyuk
Kim, Dong-Wan
Cho, Eun Kyung
Park, Keon Uk
Kim, Jin-Soo
Chun, Sang Hoon
Wang, Jangyoung
Choi, Seokyoung
Kang, Jin Hyoung
CANCER RESEARCH AND TREATMENT, 2024, 56 (01): : 48 - 60
[4] Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naive Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
Reungwetwattana, Thanyanan
Cho, Byoung Chul
Lee, Ki Hyeong
Pang, Yong Kek
Fong, Chin Heng
Kang, Jin Hyoung
Lee, Yun-Gyoo
Sen Lim, Chun
Danchaivijitr, Pongwut
Ni Lim, Yueh
Lee, Youngjoo
How, Soon Hin
Geater, Sarayut
Lee, Sung Sook
Min, Young Joo
Kim, Joo-Hang
Lee, Jong-Seok
Lee, Gyeong-Won
Soo, Ross A.
Lee, Sae Young
Choi, Seokyoung
Ahn, Myung-Ju
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (10) : 1351 - 1361
[5] Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
Cho, Byoung Chul
Ahn, Myung-Ju
Kang, Jin Hyoung
Soo, Ross A.
Reungwetwattana, Thanyanan
Yang, James Chih-Hsin
Cicin, Irfan
Kim, Dong-Wan
Wu, Yi-Long
Lu, Shun
Lee, Ki Hyeong
Pang, Yong-Kek
Zimina, Anastasia
Fong, Chin Heng
Poddubskaya, Elena
Sezer, Ahmet
How, Soon Hin
Danchaivijitr, Pongwut
Kim, Yukyung
Lim, Yeji
An, Taewon
Lee, Hana
Byun, Hae Mi
Zaric, Bojan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (26) : 4208 - +
[6] Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
Rosenfeld, Roberto
NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (06): : 619 - 620
[7] Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
Cho, Byoung C.
Lu, Shun
Felip, Enriqueta
Spira, Alexander I.
Girard, Nicolas
Lee, Jong-Seok
Lee, Se-Hoon
Ostapenko, Yurii
Danchaivijitr, Pongwut
Liu, Baogang
Alip, Adlinda
Korbenfeld, Ernesto
Mourao Dias, Josiane
Besse, Benjamin
Lee, Ki-Hyeong
Xiong, Hailin
How, Soon-Hin
Cheng, Ying
Chang, Gee-Chen
Yoshioka, Hiroshige
Yang, James C. -H.
Thomas, Michael
Nguyen, Danny
Ou, Sai-Hong I.
Mukhedkar, Sanjay
Prabhash, Kumar
D'Arcangelo, Manolo
Alatorre-Alexander, Jorge
Vazquez Limon, Juan C.
Alves, Sara
Stroyakovskiy, Daniil
Peregudova, Marina
Sendur, Mehmet A. N.
Yazici, Ozan
Califano, Raffaele
Gutierrez Calderon, Vanesa
de Marinis, Filippo
Passaro, Antonio
Kim, Sang-We
Gadgeel, Shirish M.
Xie, John
Sun, Tao
Martinez, Melissa
Ennis, Mariah
Fennema, Elizabeth
Daksh, Mahesh
Millington, Dawn
Leconte, Isabelle
Iwasawa, Ryota
Lorenzini, Patricia
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (16): : 1486 - 1498
[8] CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC
Gourd, Elizabeth
LANCET ONCOLOGY, 2018, 19 (10): : E516 - E516
[9] Safety and tolerability of lazertinib and in combination with amivantamab in advanced EGFR-mutated Japanese NSCLC
Goto, Koichi
Hida, Toyoaki
Funami, Nobuyuki
Iwasawa, Ryota
Mita, Sachiko
Yamashita, Aimi
Imanaka, Keiichiro
Kitani, Sumiko
Ohe, Yuichiro
ANNALS OF ONCOLOGY, 2021, 32 : S317 - S317
[10] Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC Reply
Cho, Byoung C.
Sethi, Seema
Spira, Alexander I.
NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (06): : 620 - 621

← 1 2 3 4 5 →